Navigation Links
Nektar Therapeutics Reports Fourth Quarter and Year-End 2011 Financial Results
Date:2/29/2012

SAN FRANCISCO, Feb. 29, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2011.

Cash, cash equivalents, and investments at December 31, 2011 were $414.9 million as compared to $315.9 million at December 31, 2010. The 2011 year-end cash balance does not include the $124.0 million payment related to the sale of Cimzia and Mircera royalties also announced today.

"In 2011, Nektar continued to demonstrate that our technology platform is capable of generating multiple new drug candidates in high value therapeutic areas such as pain, oncology and hemophilia," said Howard W. Robin, President and Chief Executive Officer of Nektar. "In Q4, we achieved excellent results in our Phase 1 program for our new opioid molecule, NKTR-181 for chronic pain, and we are advancing it into Phase 2 this year.  We also began enrollment in our Phase 3 BEACON study for NKTR-102 in metastatic breast cancer.  Finally, BAX 855, a long-acting PEGylated Factor VIII therapy for hemophilia A, entered Phase 1 clinical development with our partner, Baxter."  

The company also announced today that AstraZeneca is planning regulatory filings in the US and EU in the middle of 2013 for NKTR-118 (naloxegol) in opioid-induced constipation. Naloxegol is currently in Phase 3 clinical development as a once-daily, oral tablet for the treatment of opioid-induced constipation.

Revenue for the fourth quarter of 2011 was $15.8 million. Revenue in the fourth quarter of 2011 decreased as compared to $45.3 million in the fourth quarter of 2010 primarily as a result of the completion as of December 31, 2010 of the amortization of the $125.0 million upfront payment received in 2009 from AstraZeneca for the NKTR-118 and NKTR-119 license agreement.

Total operating costs and expenses in the fourth qu
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  The U.S. Department of Health and ... University Hospitals (UH) Case Medical Center Seidman Cancer Center ... aimed at improving care for patients with complex cancer. ... will test a unique model developed at UH to ... significant comorbidities, or demonstrated need for high health care ...
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon ... in advanced memory and analog IC solutions, today announced ... Thursday, July 24, 2014, at 7:00 a.m. Pacific Time ... results for the fiscal 2014 third quarter ended June ... via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time ...
(Date:7/10/2014)... 2014 Yesterday, former Congressman Patrick ... manufacturing facility. Rep. Kennedy and Dick Moberg ... cutting-edge research in neurological disease and treatment. ... advocate, Garen Staglin , created One Mind, ... changes that will radically accelerate the development and ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2
... Greenville, SC, announced today that its Glucommander™ 2.0 Enterprise software ... 2 - 17. Glytec,s Glucommander was the first insulin dosing ... it is the only company to achieve specific ... company cleared to offer this technology to hospitals caring for ...
... OLATHE, Kan., May 21, 2012  BD (Becton, Dickinson and ... medical technology company, and Heart to Heart International, a ... their second joint volunteer initiative to strengthen healthcare in ... the world will build upon the progress made by ...
Cached Medicine Technology:Glytec Adds Pediatric Insulin Dosing to its IV and SubQ FDA Clearances 2BD and Heart to Heart International Collaborate on Second Volunteer Service Trip to Help Improve Healthcare in Haiti 2BD and Heart to Heart International Collaborate on Second Volunteer Service Trip to Help Improve Healthcare in Haiti 3
(Date:7/12/2014)... 12, 2014 The ... Vascular Devices Market by Angioplasty Balloon ... (IVUS, OCT), IVC Filter (Retrievable), Endovascular ... analyzes and studies the major market ... U.S. and Canada. , Browse 108 ...
(Date:7/12/2014)... July 12, 2014 The Security Analytics ... 2013 to $3,376.6 million by 2019, at an expected ... 2019. The challenges to counter the increasing number of ... of outdated cyber defense systems in organizations are enormous. ... and remodeling their existing architecture to develop better and ...
(Date:7/12/2014)... 2014 Casinos in Australia ... competition from international and online casinos. Revenue is estimated ... five years through 2014-15. Greater per capita gambling expenditure ... services. Rises in discretionary income levels have also assisted ... non-essential items such as casino gambling services. Revenue is ...
(Date:7/12/2014)... PA (PRWEB) July 12, 2014 "The second ... it’s uncomfortable and painful to wear shoes," said an inventor ... special sock that prevents this from happening. , He then ... effective way to prevent the second and big toes from ... endurance while wearing shoes. Ergonomic and easy to use, it's ...
(Date:7/12/2014)... Using and carrying around a catheter bag ... Ashland, Va., decided that there needed to be an ... conceive of our design," he said. , They then ... provides an inconspicuous way to use and carry a ... promotes comfort and peace of mind. Producible in design ...
Breaking Medicine News(10 mins):Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 2Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 3Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 5Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 4
... researchers at the University of Cincinnati (UC) have found ... therapeutic treatments for obesity-related disorders, like diabetes and heart ... American Heart Association,s Scientific Session in Chicago Nov. 16. ... of cardiovascular diseases found that action by the enzyme ...
... Amanda Gardner HealthDay Reporter , TUESDAY, Nov. ... clogged arteries in addition to standard drug therapy seems ... diabetics with heart disease, new research finds. The ... annual meeting in Chicago, is part of a larger ...
... , TUESDAY, Nov. 16 (HealthDay News) -- Men who ... disease, new research suggests. The notion is based on ... a thickening of the men,s neck,s carotid artery wall. Such ... for heart disease. What,s more, the link between sleep ...
... HealthDay Reporter , TUESDAY, Nov. 16 (HealthDay News) ... were retracted by medical journals for serious errors or faked ... U.S. researchers. In fact, U.S. scientists were responsible for ... errors, as well as for 84 of the papers retracted ...
... Three-year-old Denver resident Brianna,s favorite color was yellow and her ... At 18 months she strapped on her first pair of ... loved playing with her brother and noticed everything. ... from a cardiac arrhythmia known as Long QT Syndrome. Brianna,s ...
... 16 (HealthDay News) -- New animal research has identified a ... so-called "good" cholesterol, at least in mice. Working with ... in question -- labeled "miR-33a" -- helps to regulate cholesterol ... genes. Specifically, the sequence was found to inhibit production ...
Cached Medicine News:Health News:Enzyme action could be target for diabetes, heart disease treatments 2Health News:Enzyme action could be target for diabetes, heart disease treatments 3Health News:Adding Surgery to Meds May Help Diabetics With Heart Disease 2Health News:Shorter Sleep in Men Ups Risk of Heart Disease: Study 2Health News:U.S. Scientists Commit Most Research Fraud: Study 2Health News:U.S. Scientists Commit Most Research Fraud: Study 3Health News:University of Colorado in pilot project to map defibrillators 2Health News:Scientists Find Way to Boost 'Good' Cholesterol in Mice 2
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
... The CSV-1000RS test face is used ... test presents ETDRS LogMAR acuity from 20/10 ... frequency at 12 cycles/degree. , ,The patient ... chair for ETDRS acuity and contrast sensitivity. ...
The first book to translate key medical data into clear guidelines capturing the highest treatment standards for heart disease....
... all those involved with healthcare decisions to ... latest evidence in their field of interest ... year as the volume of evidence increases. ... the best single source available for continually ...
Medicine Products: